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INTRODUCTION
In feline practice, the occurrence of arterial thrombo- 
embolism (ATE) is one of the most distressing emer- 
gency situations for the cat, the client and the veteri-
narian. Currently, in first-line practice, these patients 
are commonly euthanized at the moment of diagnosis 
(Borgeat et al., 2014). Affected patients are usually 
presented with severe pain and associated vocaliza-
tion, often combined with paralysis of the pelvic limbs 
and dyspnea or tachypnea. The most common form of 
ATE, the so-called “saddle thrombus”, is caused by 
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     BSTRACT
Feline arterial thromboembolism (ATE) is a complete or partial obstruction of a peripheral 
artery caused by a thrombus that was formed at a distant site. The most common underlying 
cause in cats is cardiomyopathy. Given the clinical presentation, often without preceding signs, 
an ATE event is considered one of the most distressing emergency conditions in feline practice. 
Often, these cats are euthanized at the time of diagnosis. However, recent scientific research has 
shown that a subpopulation of these patients may have long-term survival. In case of adequate 
treatment and follow-up, some cats survive over a year with a satisfying quality of life. Key points 
of ATE are the identification of specific prognostic factors in the individual patient in order to 
guide owner communication, the decision to treat or not to treat, individually adjusted patient 
management and regular monitoring, which are discussed in this article. 
SAMENVATTING
Feliene arterïele trombo-embolie (ATE) wordt veroorzaakt door een volledige of gedeeltelijke ob-
structie van een perifere arterie ten gevolge van trombus die gevormd werd op een andere plaats; dit 
vaak ten gevolge van cardiomyopathie. Gezien de klinische presentatie, waaraan vaak geen sympto-
men vooraf gaan, wordt ATE beschouwd als een van de meest verontrustende, spoedeisende situaties 
in de praktijk. Een aanzienlijk deel van deze patiënten wordt geëuthanaseerd op het moment van di-
agnose. Recent wetenschappelijk onderzoek heeft echter aangetoond dat sommige van deze patiënten 
een goede langetermijnoverleving kunnen hebben. Deze katten kunnen soms tot langer dan één jaar 
overleven met een goede levenskwaliteit, mits een correcte behandeling en nauwkeurige opvolging. 
Essentieel bij deze aandoening is het herkennen van specifieke prognostische factoren om de commu-
nicatie met de eigenaar te sturen en zo in samenspraak de beslissing te nemen het dier te behandelen of 
te euthanaseren. Verder zijn een individueel aangepaste therapie en gerichte follow-up van de patiënt 
belangrijk.
A
occlusion at the level of the distal aortic trifurcation. 
Diagnosis is primarily based on physical examina-
tion, with the typical clinical signs of pain, pulseless-
ness, paralysis/paresis, pallor and poikilothermy, also 
referred to as the 5 P’s. As an underlying cardiomy-
opathy is the most prevalent etiological cause, it is 
vital to recognize the presence of possible concomi-
tant congestive heart failure (CHF), as this will influ-
ence both further medical management and prognosis. 
On auscultation, the presence of inspiratory crackles, 
a gallop rhythm or a murmur is highly suggestive of 
the presence of concomitant CHF. In general, the first 
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treatment step for these painful and often tachypneic/
dyspneic cats consists of providing adequate pain re-
lief medication and a stress-free environment with ox-
ygen supplementation. Further investigations may be 
undertaken once the cat’s pain, hypercoagulable state 
and possible CHF have been addressed via analgetic, 
antithrombotic and diuretic treatment. Although many 
of these cats are euthanized at the time of diagnosis, 
a correct identification of specific prognostic factors 
obtained from results of physical examination and fur-
ther testing, enables the veterinarian to give the owner 
the best possible advice regarding further treatment, 
management and prognosis. The owner should be 
informed thoroughly about in hospital treatment and 
daily home medical care, the risk of ATE recurrence, 
presence of underlying cardiomyopathy, the need for 
monitoring, and associated costs. In this review, the 
pathophysiology of ATE is briefly explained to better 
understand clinical signs and diagnosis, with focus on 
prognostic factors aiding in the decision to treat, and 
different treatment options are discussed. 
PATHOPHYSIOLOGY
Physiological thrombogenesis
In a healthy individual, thrombus formation is co-
ordinated via interacting signalling pathways between 
platelets, coagulation factors and the endothelium, re-
sulting in hemostasis without the risk of inappropri-
ate thrombosis. Under physiological conditions, an 
intact endothelium normally produces antithrombotic 
factors, which help to maintain thromboresistance, 
whilst a damaged endothelial surface will trigger the 
coagulation cascade (Kapur et al., 2007). Further-
more, platelets will be activated via alternative path-
ways as well. The combination of these divergent 
pathways lead to a growing platelet plug with numer-
ous platelets bridged together by fibrinogen. Initially, 
the thrombus is platelet-rich but quickly becomes fi-
brin-rich as the clot grows and matures (Helenski and 
Ross, 1985; Furie and Furie, 2008; Goggs and Poole, 
2012). 
Arterial thromboembolism
The thrombus becomes lamellated as it ages and 
superficial portions can break off, or more rarely, it 
dislodges in entirety, forming the emboli that travel to 
distant sites where their size eventually exceeds ves-
sel diameter, resulting in infarction of an arterial bed 
(Collet, 1930). The thrombus causes a (partial) block 
of the obstructed artery and induces vasoconstriction 
of the collaterals, reducing perfusion and oxygenation 
of the tissue distal to the obstructed vessel. In cats 
with cardiomyopathy, the left auricular appendage is 
usually the site of thrombus formation. Certain arte-
ries, e.g. the distal aorta, are more prone to obstruc-
tion, due to their anatomical conformation (Figure 1). 
The most common underlying cause of thrombo-
genesis leading to an ATE event, is cardiac disease, 
and in the feline population, this is most commonly 
(in approximately 69% of the cases) cardiomyopathy 
(Smith et al., 2004). Feline cardiomyopathy predis-
poses to formation of intracavitary thrombi due to 
blood stasis, endothelial injury and a hypercoagulable 
state, fulfilling all components of the Virchow triad 
(Welles et al., 1994; Schober and Maerz, 2006; Stokol 
et al., 2008). 
Blood stasis
Blood stasis is primarily seen in the left atrium, 
when it is dilated secondary to the underlying cardiac 
disease. Low blood flow velocities have been linked 
to spontaneous echo contrast or ‘smoke’ in the left 
atrium and left auricular appendage, which can easily 
be detected using echocardiography (Figure 2). 
Figure 1. A thrombus obstructing the distal aorta at 
the level of the bifurcation (Photograph courtesy of P. 
Smets). 
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Endothelial function
Secondary to left atrium enlargement, increased 
intra-atrial pressure and stretch have been associated 
with endothelial injury, exposing subendothelial col-
lagen or causing endothelial dysfunction, which fa-
cilitates platelet adhesion with subsequent activation 
and aggregation (Laste and Harpster, 1995; Smith et 
al., 2003; Furie and Furie, 2008). 
Platelet function
The presence of a hypercoagulable state in cats is 
controversial, but the clinical occurrence of thrombo-
sis has been associated with platelet hypersensitivity, 
increased procoagulantia and decreased antithrom-
bin levels (Jandrey et al., 2008; Brazzell and Borjes-
son, 2007). However, neither left atrial size nor CHF 
were associated with hypercoagulability in a study 
by Stokol et al. (2008). This suggests that a subset 
of cats with cardiomyopathy may be hypercoagulable 
and develop ATE irrespective of atrial enlargement 
(Welles et al., 1994; Stokol et al., 2008). 
Having discussed Virchow’s triad and its different 
components in association with the pathogenesis of 
arterial thromboembolism, it can be concluded that an 
ATE event is a multifactorial process, with the most 
important factor being blood flow stasis associated 
with a dilated left atrium; other contributing factors, 
such as endothelial damage or hypercoagulability, 
may be involved to a lesser extent (Fuentes, 2012).
PREVALENCE AND SIGNALMENT
In several studies, divergent prevalence numbers 
have been shown, ranging from 0.6% in referral popu-
lations to 0.3% in general practice (Smith et al., 2003; 
Borgeat et al., 2014). In different studies, an ATE 
prevalence has been reported from 12 up to 21% in 
cats that have been diagnosed with HCM (Rush et 
al., 2000). Tomcats are overrepresented. This might 
reflect the male predisposition to cardiomyopathy, 
which is hence likely to be gender biased. There is no 
real breed predisposition, purebred cats are affected as 
well as domestic short- and longhair cats (Baty et al., 
2001; Ferasin et al., 2003). Age at presentation with 
ATE ranges from one to twenty years, but the median 
age is eight to nine years (Laste and Harpster, 1995). 
HISTORY AND CLINICAL SIGNS
Affected patients are usually presented with severe 
pain and associated vocalization, often combined with 
paralysis of the pelvic limbs and dyspnea or tachy-
pnea. Because the trifurcation of the distal aorta is the 
most prevalent site of obstruction, an ATE event often 
leads to paresis or paralysis of the pelvic limbs due to 
ischemic neuromyopathy, although one leg might be 
more affected than the other. Infarction of one tho-
racic limb is the second most common clinical pre-
sentation of ATE in cats, with reported frequencies of 
12-19% (Hogan and Brainard, 2015). An obstruction 
of the brachial artery will lead to paresis or paraly-
sis of the affected thoracic leg. Tetraparesis has been 
reported as well (Bowles et al., 2010). Clinical signs 
might be different with embolization sites other than 
the distal aorta, the communal iliacal arteries, or the 
brachial artery and are dependent on the secondary af-
fected and ischemic organs. The majority of cats with 
an ATE event that are presented in practice have no 
known history of cardiomyopathy. Severe pain and 
often paralysis of the pelvic limbs are often the first 
clinical signs noticed. Its dramatic presentation and 
the lack of preceding clinical signs make ATE one of 
the most distressing conditions encountered in feline 
practice (Fuentes, 2012). 
PHYSICAL EXAMINATION
Besides pain and distress often in combination 
with vocalization, dyspnea and tachypnea, the clini-
cal signs are associated with the affected site of ob-
Figure 2. Spontaneous echocardiographic contrast, 
also known as ‘smoke’, can be distinguished within 
the enlarged left atrium (arrows) (LA: left atrium; Ao: 
aorta) (Photograph courtesy of P. Smets).
Figure 3. Abnormal stance (knuckling of the metatarsus) 
with paralysis of the right hind limb due to ATE 
(Photograph courtesy of P. Smets).
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struction. As the trifurcation of the distal aorta is the 
most affected site, representing 71% of the cases in 
one large study, paresis or paralysis of either or both 
hind legs due to a so called “saddle thrombus” are 
most commonly seen. Studies have shown that only 
one limb may be affected in up to 26% of cats with 
ATE (Smith et al., 2003) (Figure 3). The diagnosis of 
saddle thrombus can be made from the physical ex-
amination alone, based on the following signs: pain, 
paralysis/paresis of the hind limbs, pulselessness, pal-
lor and poikilothermy, also referred to as the 5 P’s. 
The combination of pelvic limb lower motor neuron 
signs with absent femoral pulses and cold extremities 
is pathognomonic for ATE and allows differentia-
tion with a neurological cause. Pulselessness might 
be hard to differentiate in the front legs, but in addi-
tion to cold extremities, the foot pads of the affected 
limb(s) are often pale or cyanotic (Figure 4). If the 
embolized thrombus is small, rapidly lyzed or colla- 
teral function is quickly re-established, motor function 
may be present, and foot pads may be well-perfused 
by the time the cat is presented. The last P, namely 
the poikilothermy, refers to the fact that the majority 
(up to 72%) of  ATE cats are presented with a reduced 
rectal temperature, which is considered to be a poor 
prognostic parameter when it is below 37.2°C (Smith 
et al., 2003; Borgeat et al., 2014). The rectal tone and 
urinary bladder function are typically maintained. 
Furthermore, signs of CHF, e.g. dyspnea and 
tachypnea, might be present. It is vital to recognize the 
presence of possible concomitant heart failure, as this 
will influence the further medical treatment, manage-
ment and prognosis. Congestive heart failure has been 
reported in 44% to 66% of cases (Smith and Tobias, 
2004). An increased respiration rate should not auto-
matically be interpreted as diagnostic of CHF, since 
the animal may be tachypneic only due to severe pain. 
Re-assessment after adequate analgesia is necessary 
in this case. On the contrary, the presence of crackles, 
a murmur, gallop sound or arrhythmia detected during 
thoracic auscultation are suggestive for CHF and pos-
sible pulmonary edema. However, in 40% of the cats 
presented with ATE, auscultation is unremarkable, de-
spite the fact that myocardial disease is the underlying 
cause in the vast majority of cases (Laste and Harpster 
1995). Therefore, underlying heart disease based on 
a normal auscultation cannot be ruled out (Wagner et 
al., 2010). 
DIFFERENTIAL DIAGNOSIS AND DIAGNOS-
TIC TOOLS
Differential causes of acute posterior paresis in-
clude: trauma, intervertebral disc extrusion, spinal 
lymphoma and other neoplasias, fibracartilaginous 
embolism-induced infarction (Volk et al., 2011). 
Acute forelimb paresis can be caused by trauma, for-
eign body, brachial plexus avulsion.
It is important to emphasize that administration 
of adequate pain medication (usually opioids), oxy-
gen supplementation in case of dyspnea and reducing 
stress to an essential minimum are vital parts of the 
first crucial management step and precedes any fur-
ther diagnostic tests.
Thoracic radiographs
Thoracic radiographs are currently the most re-
liable diagnostic test in order to confirm or exclude 
the presence of CHF, especially if thoracic ausculta-
tion was unremarkable; moreover, they rule out other 
possible, pulmonary pathologies, which might cause 
tachypnea or dyspnea. However, in one study, about 
11% of cats with thromboembolism had normal car-
diac silhouettes (Laste and Harpster, 1995). In cats 
with respiratory distress, thoracic radiographs should 
be postponed until the patient is stabilized, as manipu-
lation might cause further (sudden) clinical deteriora-
tion.
Echocardiography
Once the patient is clinically stable, an echocardio-
graphic examination is advised in order to diagnose a 
possible underlying heart disease. The vast majority 
of these patients have a dilated left atrium, possibly 
in combination with spontaneous echogenic contrast 
or ‘smoke’ visible in the left atrial lumen (Figure 2). 
‘Smoke’ indicates an increased risk of embolic stroke 
in human patients, and is believed to be associated 
with an increased risk of ATE in cats (Schober and 
Maerz, 2006). However, a small subset of cats pre-
sented with ATE do not have cardiac abnormalities on 
echocardiography.
Figure 4. Cyanotic left hind limb footpad and the pale 
pink right hind limb footpad in this cat with asymmetric 
ATE of the distal aorta (Photograph courtesy of P. 
Smets).
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Although the diagnosis of ATE in cats with pelvic 
limb paresis/paralysis is usually based on the distinc-
tive clinical findings rather than imaging, it is com-
monly possible to identify the thrombus in the ter-
minal aorta using ultrasound imaging. However, the 
absence of a visible thrombus does not rule out ATE. 
Where no underlying cardiac disease is identified, 
further local imaging of the occluded artery is more 
justifiable (Fuentes, 2012). 
Additional tests
Biochemistry tests
Biochemistry tests may show a variety of abnor-
malities, e.g. azotemia, hyperglycemia and phospha-
temia. Azotemia can be either prerenal secondary due 
to reduced renal perfusion or renal due to thrombo-
embolism of a renal artery. Hyperglycemia is often 
stress-related. Furthermore, serum creatine kinase 
is often severely increased due to muscle ischemia. 
Furthermore, alanine aminotransferase values are of-
ten elevated (Smith et al., 2003). Potassium values 
are variable and cats may actually be hypokalemic 
on presentation, but may develop hyperkalemia once 
perfusion has been restored. Finally, hypocalcemia 
and hypernatremia have also been reported. In older 
cats, total thyroxine levels should be measured as hy-
perthyroid cats may be at an increased risk of ATE 
irrespective of any cardiac changes (Laste and Harp-
ster, 1995). Coagulation tests are frequently normal, 
although D-dimers may be elevated (Bedard et al., 
2007; Fuentes, 2012). 
Blood pressure measurement
Doppler blood pressure assessment may be used to 
confirm the lack of pulse in the affected limb. 
Electrocardiography
Electrocardiography was shown to be informative 
in a large retrospective study of cats presenting with 
ATE, with 85% of affected cats having ECG changes 
in heart rate or rhythm. The most common ECG ab-
normalities included a left ventricular enlargement 
pattern, with large R-waves in leads I and aVL (39%), 
sinus tachycardia (28%), ventricular premature beats 
(19%), supraventricular premature beats (19%), pro-
longation of the QRS interval (16%) and a left atrial 
enlargement pattern (16%), with a broad, bifid P wave 
in lead II (Laste and Harpster, 1995). 
DECISION TO TREAT AND PROGNOSIS
Despite the fact that these patients are often pre-
sented with acute limb paralysis in severe pain and 
distress, which is often perceived by both the owners 
and veterinary practitioner as inevitably disastrous, a 
significant subset of cats may recover and lead good-
quality lives. The general prognosis is poor with a 
survival rate of 33% to 39%, but several cats may dis-
play positive prognostic factors indicative of higher 
survival rates and better mid- to long-term prognosis. 
Those positive prognostic factors are the absence of 
CHF, rectal temperature at the moment of presen-
tation >37.2°C, (partial) presence of motor func-
tion, and the site of thromboembolism and associ-
ated affected limbs or other organs (Schoeman, 1999; 
Borgeat et al., 2014). Although many of these cats are 
euthanized upon diagnosis, a correct identification of 
specific prognostic factors obtained from results of 
physical examination and further testing, enables the 
veterinarian to give the owner the best possible advice 
regarding further treatment, management and progno-
sis. Despite the generally bad prognosis, a study by 
Smith et al. (2003) showed that rates of survival to 
discharge improved over a ten-year period, with 73% 
of cats surviving to discharge in the last year of study. 
As many as 70–80% of cats with a single limb af-
fected survived to discharge, with up to 90% survival 
rates in cats presenting with some motor function. 
Hypothermia appeared to be one of the most reliable 
markers of reduced initial survival in this study, with 
<50% chance of survival to discharge in cats with a 
rectal temperature <37.2°C on presentation. 
Pain is severe in the initial 24 hours, but decreases 
substantially after the first 48 hours. The cranial tibial 
and gastrocnemius muscles may become firm within 
ten to twelve hours post-embolization due to ischemic 
myopathy, and ischemic nerve damage may result in 
‘dropped hocks’ as well as loss of distal sensation. 
The muscles become softer 24 to 72 hours later. How-
ever, in some cats, the degree of firmness increases 
over the first few days, suggesting poorer perfusion. 
Perfusion and femoral pulses frequently return within 
three to five days, although in case of severe tissue 
ischemia, there is a risk of skin and muscle necrosis 
(Figure 5). This usually manifests within the first two 
weeks and may lead to loss of toes or decision for 
limb amputation in severe cases (Smith et al., 2003). 
Although not well-quantified, many cats may regain 
Figure 5. Skin necrosis of the right hind limb, secondary 
to an ATE event (Photograph courtesy of L. Locquet).
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some to all motor function of the pelvic limbs within 
four to six weeks from the initial event either due to 
re-establishment of the collateral vascular network, 
intrinsic dissolution of the embolus, or recanalization 
of the obstructed aorta (Smith et al., 2003).
Owners should be aware that their cat might not 
survive to discharge or might develop a following 
episode of ATE in the (nearby) future. However, es-
pecially cats without CHF and with only one affected 
limb, remaining motor function and a rectal tempera-
ture above 37.2° have a substantially better prognosis 
and may regain partial or complete normal function. 
Reported ATE recurrence rates range from 24-75%, 
but because cardiomyopathy is the most prevalent 
etiological cause, the major cause of death in this sub-
group is actually CHF, and not a recurrent episode of 
ATE (Rush et al., 2000; Lunsford and Mackin, 2007; 
Payne et al., 2015). Reports of average long-term 
survival vary between 51 and 350 days (Atkins et 
al.,1992; Schoeman, 1999).
TREATMENT OF ATE
Thrombolytic therapies
Several approaches have been tested in order to 
remove the obstructing thrombus, but the small size 
of cats limits minimal invasive embolectomy tech-
niques. Moreover, anesthetic and surgical complica-
tions cause high mortality rates. Therefore, this type 
of treatment is currently contraindicated (Reimer et 
al., 2006). Medical thrombolytic therapy with strep-
tokinase and tissue plasminogen activator (t-PA) have 
both been reported in the cat and dissolution of the 
thrombus has been documented up to 18 hours after 
initial clinical signs (Moore et al., 2000; Welch et al., 
2010). However, sudden reperfusion of ischemic tis-
sues flushing ischemic metabolites, such as potassium 
and free oxygen species into the bloodstream, leading 
to reperfusion injury, a life-threatening complication 
causing arrhythmias, renal dysfunction and acid-base 
disturbances. This has been reported in 40% to 70% 
of cats receiving thrombolytic therapy and represents 
the most common cause of death, with survival rates 
ranging from 0% to 43% (Lunsford and Mackin, 
2007; Welch et al., 2010). Given these possible lethal 
complications, thrombolytic therapy should not be 
administered without thorough consideration of the 
benefit-to-risk ratio, which should be evaluated for 
each individual case and its clinical presentation. If 
available, thrombolytic therapy should be considered 
in rare cases of cerebral, splanchic or renal infarction, 
while a cat with a unilateral limb infarction is more 
likely to achieve complete recovery with conservative 
therapy (Reimer et al., 2006). The high costs also limit 
medical thrombolytic therapy in veterinary medicine.
Since thrombolytic therapy is often not possible 
or even contraindicated, the mainstay of treatment 
is prevention of continued thrombus formation. The 
two major categories of antithrombotic drugs are an-
tiplatelet agents and anticoagulants (Fuentes, 2012; 
Hogan and Brainard, 2015). Doses for these drugs can 
be found in Table 1.
Antiplatelet agents
Antiplatelet agents are currently the mainstay of 
treatment for feline ATE, because they may improve 
collateral flow by reducing the amount of vasoactive 
substances that are released by the platelets (Schaub 
et al., 1982; Arrebola et al., 2004). Some veterinary 
cardiologists recommend a combination of two anti- 
platelet agents (clopidogrel + aspirin) in cats, al-
though there are no studies in cats available about 
this approach (Fuentes, 2012). This approach is typi-
cally limited to those patients that appear to be at par-
ticularly increased risk of ATE, i.e. those cats, which 
continue to have spontaneous echogenic contrast or 
develop a left atrial thrombus in spite of already re-
ceiving therapy (Tan et al., 2010).
Aspirin
Aspirin irreversibly inhibits the production of 
thromboxane A2 (TXA2), a potent pro-aggregating 
and vasoconstrictive molecule. This effect lasts for 
the lifetime of the platelet. Treating feline patients 
with aspirin prevent vasoconstriction of collateral cir-
culation. However, cats are still at risk to develop ATE 
despite treatment, as other TXA2-independent path-
ways may still result in platelet aggregation (Lunsford 
and Mackin, 2007). Smith et al. (2003) have shown 
that the incidence of ATE with low-dose aspirin (5mg/
cat q72h) compared to high dose aspirin (40mg/cat 
q72h), was the same. When applying the latter dose, 
adverse effects are typically gastrointestinal, includ-
ing anorexia and vomiting secondary to gastric ulcer-
ation, and have been reported in up to 22% of treated 
cats. Aspirin has been used for the prevention of re-
currence of ATE in cats that already had an episode 
of ATE (secondary prevention) with recurrence rates 
ranging from 17% to 75%, and median survival times 
from 117 to 192 days. However, the recent prospec-
tive FATCAT study, evaluating secondary preven-
tion of ATE in cats, has shown aspirin to be inferior 
to clopidogrel for secondary prevention (Hogan et 
al.,2015). If monitoring of aspirin therapy is desired, 
platelet aggregation should be performed before and 
after at least two weeks of therapy to determine the 
degree of platelet inhibition. However, it should be 
mentioned that only a minority of institutions offer 
this aforementioned test.
Clopidogrel
Clopidogrel is a specific and irreversible ADP re-
ceptor antagonist, as well as a direct platelet antago-
nist, inhibiting both primary and secondary platelet 
aggregation. Additionally, clopidogrel also has been 
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Figure 6. Skin necrosis in the same cat, healing by 
secondary intention, secondary to an ATE event 
(Photograph courtesy of L. Locquet).
shown to impair the platelet release reaction and to 
have vasomodulating effects, maintaining collateral 
circulation parallel to the occluded artery. Adverse 
effects are rare, although there are empirical reports 
of sporadic hypersalivation due to the bitter taste of 
the drug, vomiting and icterus (Hogan et al., 2015). 
Clopidogrel has been shown to be superior to aspirin 
for secondary prevention, with a lower ATE recur-
rence rate of 49% (versus 75%) and a one-year recur-
rence rate of 36% (versus 64%). Additionally, clopi-
dogrel has been associated with longer median time 
to event (443 days) than aspirin (192 days) (Hogan et 
al., 2015). As with aspirin, monitoring of clopidogrel 
therapy is rarely performed in veterinary medicine but 
ADP-induced platelet aggregation is considered the 
gold standard. 
Anticoagulants
Anticoagulants inhibit the coagulation cascade by 
interfering with formation of one or more active coagu- 
lation factors. In feline medicine, they are now less 
commonly used than anti-platelet agents, but the new 
classes of drugs, such as factor Xa-inhibitors may 
hold promise for future use in cats. 
Unfractionated heparin
Heparin inhibits the coagulation process by counter- 
acting thrombin and activate factors XII, XI, I and 
IX (Lunford and Mackin, 2007). Heparin is adminis-
tered SC, but if the cat is in shock, the first dose may 
also be administered IV. Heparin is often used early 
in the course of feline ATE to reduce extension of the 
existing thrombus, and risk of hemorrhages appears 
to be small. Serial measurement of aPTT has histori-
cally been used to monitor effect, with desired aPTT 
1.5-2.0 times above baseline. However, in one study, 
it has been shown that aPTT does not correlate well 
with plasma heparin levels and anti-Xa monitoring 
may be a better approach (Smith et al., 2004).  
Low molecular weight heparins
Given its longer half-life and more predictable dose 
response, low molecular weight heparin (LMWH) has 
largely superseded unfractioned heparin in the pre-
vention of human deep vein thrombosis, enabling the 
practitioner to adjust the dose more accurately accord-
ing to the body weight without the need to monitor 
the coagulation effects (Lunford and Mackin, 2007). 
Due to the pharmacokinetic profile and positive clini-
cal studies in humans, there has been great interest in 
the LMWHs for the prevention of ATE in cats (Smith 
et al., 2004; Vargo et al., 2009). Alwood et al. (2007) 
compared enoxaparin, dalteparin and unfractrioned 
heparin in healthy cats. Only unfractionated heparin 
showed adequate anti-Xa activity. However, the anti-
Xa activity does not always correlate with clinical anti- 
thrombotic effects. There is one retrospective study, 
in which dalteparin was compared to warfarin, and 
no significant difference in ATE recurrence rate (43% 
versus 24% respectively) or median survival time 
(255 days versus 69 days) was demonstrated (Defran-
scesco et al., 2003). At this timepoint, for the use in 
the acute in-hospital treatment, there is no clear bene-
fit of LMWH over unfractionated heparin, whereas 
the cost of the former is much higher. 
Warfarin
Warfarin blocks the effects of vitamin K, neces-
sary for coagulation factors II, VII, IX and X to be 
activated. However, it is highly protein-bound, has 
numerous possible interactions with other medica-
tions, and has unpredictable pharmacodynamics and 
pharmacokinetics, with the latter being influenced by 
both disease state and dietary components. This leads 
to difficulties associated with its use, safety and effect 
(Lunsford and Mackin, 2007). Given the unpredic-
table effect, feline patients exhibit a wide and variable 
inter-individual and intra-individual anticoagulant 
response to warfarin, resulting in poor results in studies 
on warfarin use in cats, with cats with continued 
thrombogenesis and cats with severe hemorrhages. 
ATE recurrence rates for cats receiving warfarin range 
from 24% to 53% with estimated mean survival times 
of 255 days (Defranscesco et al., 2003). 
Conclusively, necessary regular monitoring of 
prothrombin time and corresponding blood sampling 
in order to assess the effect of warfarin, compromises 
the life quality of these patients. Although the superio- 
rity of warfarin has been demonstrated for the preven-
tion of ATE in humans, the issues with variability in 
clinical response, requirement for frequent monitor-
ing and bleeding complications have resulted in a rare 
use of warfarin for thromboprophylaxis in cats.
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Table 1. Possible m
edical m
anagem
ent options in the initial and further treatm
ent of ATE (adapted from
 Luis-Fuentes, 2012).
 
Drugs 
Dose 
Advantages 
Disadvantages 
Com
m
ents
Analgesics 
M
ethadone 
0.2-0.4m
g/kg slow
 IV q4-6h 
Potent analgesia 
 
M
u agonist, titrate to effect
 
 
 
Vom
iting is rare 
 
 
Fentanyl 
3μg/kg slow
 IV, follow
ed 
Potent analgesia 
M
u agonist, titrate to effect
 
 
by 2-5 μg/kg/h CRI 
 
 
 
Buprenorphine 
0.02m
g/kg IV
 or IM
 q6h 
W
idely available 
N
ot sufficiently potent 
Partial opioid agonist
 
 
 
 
for severe pain 
CH
F treatm
ent 
Furosem
ide 
1-2m
g/kg q1-8h IV
 
R
apid diuresis 
M
ay cause azotaem
ia and 
C
onfirm
 tachypnea is due to
 
 
 
 
hypokalem
ia 
pulm
onary oedem
a w
ith
 
 
 
 
 
thoracic X
-ray
 
Pim
obendan 
0.625-1.25 m
g/cat q12h PO
 
M
ay im
prove hypotension 
O
ral m
edications difficult 
M
ay w
orsen outflow
 tract
 
 
 
 
w
ith severe respiratory distress 
obstruction, so do not use if
 
 
 
 
 
m
urm
ur is present
Anticoagulants 
U
nfractionated 
100-250 U
/kg IV, 50- 
Inexpensive 
H
igh doses result in a m
ore  
D
o not use IM
- risk of
 
heparin 
250 U
/kg SC q6h 
M
ay reduce expansion or  
rapid onset of effect com
pared 
bleeding 
 
 
 
xtension of throm
busEffect 
w
ith low
er doses.
 
 
 
can be m
onitored by 
Risk of haem
orrhage
 
 
 
prothrom
bin tim
e 
appears to be sm
all
  
Enoxaparin 
1m
g/kg q8-12h SC 
Reduced risk of hem
orrhage? 
Expensive  
Effective dose and dosing
 
 
 
 
 
interval unkow
n 
 
D
alteparin 
100 IU
/kg q8-12h SC 
Reduced risk of hem
orrhage? 
Expensive  
Effective dose and dosing
 
 
 
 
 
interval unkow
n 
  
W
arfarin 
0.5m
g/cat q24h PO
 
Inexpensive 
U
npredictable pharm
acokinetics  
D
O
 N
O
T U
SE 
 
 
 
Effect can be m
onitored w
ith 
H
igh risk of haem
orrhage
 
 
 
international norm
alized ratio 
Requires frequent blood sam
pling
 
 
 
 
to m
onitor effects 
Antiplatelets 
A
spirin 
75m
g/cat q72h PO
 (high dose) 
Inexpensive 
Inferior to clopidogrel for 
Low
 dose m
ay also be given
 
 
or 5m
g/cat q72h PO
 (low
 dose) 
M
ostly w
ell-tolerated 
secondary prevention of ATE 
q48h
 
 
 
Risk of hem
orrhage low
 
 
 
 
Clopidogrel 
Loading dose of 75m
g 
M
ostly w
ell-tolerated 
Bitter taste, m
ay cause salivation 
 
 
Chronic: 18.75m
g/cat q24h PO
 
M
ay have additive effect
 
 
 
w
ith aspirin 
 
 
 
Superior to aspirin for secondary
 
 
 
prevention of ATE
 
 
 
Risk of hem
orrhage low
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Newer anticoagulants
Recently, in human medicine, a wide variety of 
new anticoagulant drugs have been developed to pre-
vent deep venous thrombosis, pulmonary embolism 
and ATE. Examples of these newly developed antico-
agulants are abciximab (a glycoprotein IIb/IIIa anta-
gonist), dabigatran (a direct thrombin inhibitor) and 
factor Xa-inhibitors, e.g. fondaparinux, rivaroxaban 
and apixaban. These drugs have been studied thor-
oughly within human medicine and were designed 
with excellent efficacy. They exhibit relatively low 
bleeding risks and generally do not require clinical 
monitoring. Studies regarding the use of these medi-
cations within veterinary medicine are currently lack-
ing. It is expected that factor Xa-inhibitors will likely 
have a major impact on clinical prophylaxis or ATE 
in cats. Given the aforementioned characteristics, it 
would dramatically improve the clinical management 
of cats at risk of ATE, as current prophylactic proto-
cols are still often based on theoretic effects and bene-
fits, assumed bleeding risk and clinical experience 
(Hogan, 2017).
General treatment approach
Currently, a considerable part of these patients are 
euthanized upon diagnosis, given the sudden onset 
of devastating clinical signs, often without preceding 
warning. Given the very painful nature of this condi-
tion and due to welfare issues, euthanasia should be 
discussed and considered indeed, in case no adequate 
pain relief medication can be provided. Furthermore, 
failure to receive aspirin, clopidogrel or both is an 
independent predictor of euthanasia or death within 
seven days (Borgeat et al., 2014). However, if ade-
quately treated, the majority of these patients are 
fairly stable within 48-72 hours. Aforementioned 
prognostic factors, i.e. the presence of CHF, bilateral 
hind limb paralysis versus only one limb affected, 
rectal temperature, etc., enable the clinician to have 
a more substantiated discussion regarding prognosis 
and expected success rate. Therefore, veterinarians 
and owners should consider therapy for at least the 
first 72 hours and not make a decision for immediate 
euthanasia (Hogan et al., 2015).
Therapy and management of a cardiogenic ATE 
(CATE) event can be divided in an acute and long-
term component. The management of acute CATE in-
cludes: 1. provide pain management, 2. induction of 
a hypocoagulable state to reduce continued thrombus 
formation, 3. improve blood flow to the infarcted arte-
rial bed, 4. treat concurrent CHF if present, 5. provide 
supportive care.
This approach does not require extensive financial 
resources, nor does it necessitate a prolonged hospital 
stay.
First 60 minutes
Even before having a thorough discussion with the 
owners regarding further treatment possibilities, anal-
gesia has to be administered (Figure 7). Opioid anal- 
getics, e.g. methadone, buprenorphine or fentanyl, 
should be administered at adequate doses and titrated 
to effect. Furthermore, in case of respiratory distress, 
oxygen supplementation should be provided without 
distressing the patient any further. Inspiratory crack-
les and a gallop rhythm are highly suggestive for the 
presence of concomitant CHF. If severe pulmonary 
edema secondary to CHF, is expected, an intravenous/
intramuscular bolus of furosemide should be adminis-
tered at 1-2mg/kg and repeated to effect. The bolus 
can be repeated hourly or even more frequently, de-
pending on the severity of the respiratory distress and 
clinical response. Once the cat has been clinically sta-
bilized, thoracic radiographs should be taken in order 
to confirm the presence of suspected CHF (Fuentes, 
2012). 
The next priority is to start antithrombotic treat-
ment in order to induce a hypocoagulable state. Given 
the acute onset of clinical signs, the embolus has of-
ten broken off only recently and hence has a ‘fresh’ 
surface, which activates and stimulates the coagula-
tion system, resulting in additional thrombus forma-
tion and vasoconstriction of the collateral circulation. 
The basic principle of this antithrombotic treatment is 
to avoid further extension of the existing thrombus, 
prevent additional thrombus formation and shift the 
intrinsic thrombosis/thrombolysis equilibrium toward 
thrombolysis. Hence, it is important to realize that the 
main goal is not to lyze the already developed throm-
bus (Hogan, 2017). 
The value of unfractionated heparin or LMWHs 
for this use has been shown to be quite variable in cats. 
The recommended dosing regimen for unfractionated 
heparin is 250 to 375 IU/kg intravenously initially, 
followed by 150 to 250 IU/kg subcutaneously every 
six to eight hours. Heparin should not be adminis-
tered intramuscularly because of the risk of injection 
site hemorrhage. Obtaining a coagulation panel that 
includes platelet count, PT and aPTT before unfrac-
tionated heparin administration is ideal so drug ef-
fect can be documented by repetitive re-evaluation of 
these aforementioned values during heparin therapy. 
Although not supported by clinical data, prolongation 
of the aPTT of 1.5 to 2.0 times the baseline value is 
considered an adequate drug response (Lunsford and 
Mackin, 2007). As unfractionated heparin is relatively 
inexpensive and readily available, it is a good choice 
for acute therapy. 
Compared to unfractionated heparin, low molecu-
lar weight heparins have similar hemostatic effects; 
however, the costs are considerably higher. The cur-
rent recommended protocols for dalteparin in cats 
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are 100 IU/kg subcutaneously every 24 to 12 hours 
and for enoxaparin 1.5mg/kg SC every 24 to 12 
hours, respectively. In a recent pilot study, it has been 
demonstrated that enoxaparin, when administered at a 
dosage of 1 mg/kg SC q12h already produced an anti-
thrombotic effect in a venous stasis model in clinical-
ly healthy cats (Van De Wiele et al., 2010). Although 
they have a beneficial pharmacokinetic profile, allow-
ing them to be administered twice daily, this effect 
is minimal in the acute management of ATE, so the 
higher cost of the LMWH may not be justified.
Increasing perfusion to the infarcted region can be 
attempted by increasing blood flow through the col-
lateral network using antiplatelet drugs, which may 
be helpful by impairing platelet activation, and hence 
the vasoactive substances released from platelets. Ei-
ther aspirin or clopidogrel can be used. Studies have 
shown that aspirin reduces the amount of released 
thromboxane A2, which results in an improvement 
of the collateral flow (Schaub et al., 1982). However, 
in these studies, very high aspirin doses were used 
(150mg/kg), which might cause toxic adverse effects. 
Lower doses have not been evaluated with regard to 
the effect on the collateral network. Similar results 
have been noted after clopidogrel administration at a 
dose of 75mg per cat, due to inhibition of platelet ac-
tivation and secondary reduction of serotonin release. 
An alternative approach is to use oral platelet in-
hibitors such as aspirin or clopidogrel from the start, 
and not include heparin at all. Some clinicians use 
both aspirin and clopidogrel together as early as pos-
sible (Fuentes, 2012).  
Direct-acting arterial vasodilators such as acepro-
mazine have not been shown to have an effect on the 
collateral network, and are contraindicated as hypo-
tension may result in further reduced perfusion.
 
First 24 hours
Further tests and investigations may be undertaken 
once the cat’s pain, ATE and possible CHF have been 
addressed. Renal values and electrolytes, especially 
potassium, should be evaluated and an echocardio-
graphic examination should be performed in order to 
identify possible underlying cardiomyopathy.
Intravenous fluid therapy may assist the treatment 
of azotemia and the removal of metabolic toxins. 
However, as a substantial proportion of the patients 
suffers from CHF, it is recommended to cautiously use 
parenteral fluid therapy only in cases that would bene- 
fit from its use, which is a minority (Fuentes, 2012). 
Vigilant monitoring of respiratory rate, effort and aus-
cultation for the development of a gallop rhythm is 
particularly important in these patients. Furthermore, 
in these particular cases, the diuretic dose should be 
reduced and other approaches to stimulate the heart 
function should be assessed. 
Given its positive inotropic and lusitropic effect, 
pimobendan can be administered, although pharmo-
cokinetic and dynamic studies of pimobendan in cats 
are scarce at the moment and its use is currently not 
authorized in cats (MacGregor et al., 2011). Pimoben-
dan is not a standard part of the treatment strategy in 
CATE. Moreover, it may be contraindicated if systolic 
anterior motion of the mitral valve causing dynamic 
left ventricular outflow tract obstruction has been 
Figure 7. Approach to the cat with ATE: first hour (adapted from Luis-Fuentes, 2012). 
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diagnosed based on the echocardiographic examina-
tion. In this case, it may lead to hypotension (Gordon 
et al., 2012; Gordon and Côté, 2015).
Furthermore, an intensive care setting is essential 
in the further treatment of ATE cats in order to ensure 
that these patients are comfortable and early signs of 
possible complications are detected. Despite the cats 
being monitored regularly, manipulation should be 
kept to an essential minimum to prevent any further 
distress. 
24-48 hours post-ATE
Further investigations/monitoring
Pain usually decreases and resolves over the first 
24-36 hours, with an easily identified improvement, 
both in general as of the warmth, pulse quality and 
motor function of the affected limb(s) in particular 
(Hogan, 2017). Even without specific thrombolytic 
measures, the pulse strength will often improve with-
in four to five days. This reflects an improved per-
fusion of the affected limb(s). Severe ischemic nerve 
damage may take weeks to improve. 
In this particular phase, identifying early warning 
signs of possible complications or adverse effects is 
vital, although often challenging. The latter may in-
clude CHF, reperfusion injury, azotemia and local 
consequences of ischemic tissue necrosis. Reperfu-
sion of ischemic tissue may cause fluctuating serum 
potassium levels, acid-base balance disturbances 
and elevated reactive oxygen species concentrations, 
which might be life-threatening. This may cause the 
patient to deteriorate dramatically and often very sud-
den, whilst often making apparent good progress be-
fore the reperfusion injury (Fuentes, 2012). In patients 
with ATE, only partially obstructing the affected blood 
vessel, reperfusion injuries are often less severe. Car-
diac and neuromuscular cells are most sensitive for 
hyperkalemia, resulting in generalized lethargy and 
bradycardia, possibly evolving towards potential le-
thal atrial standstill and a comatose state. These can 
be confirmed with blood tests and electrocardiogram. 
Hyperkalemia should be treated accordingly with ad-
justed fluid therapy, glucose, (humilin) insulin, and/ or 
calcium bicarbonate, dependent on the exact elevated 
potassium levels and its availability.
Management
Antithrombotic treatment with clopidogrel, pos-
sibly in combination with aspirin, should be contin-
ued (Hogan et al., 2015). Despite the fact that most 
patients will be comfortable after 24 hours, the anal-
getic treatment should be continued (Table 1). Warm 
ambient temperatures may stimulate circulation and 
counteract muscle contraction. Application of heat 
pads or other external heat sources is contraindicated 
because of the risk for thermal injury to the infarcted 
tissues. Furthermore, nutritional support is a critically 
important aspect that may be overlooked. If the cat 
is not eating or the caloric intake is inadequate, ad-
ministration of mirtazapine, an appetite stimulant, or 
assisted enteral feeding should be considered (Hogan, 
2017). Self-mutilation of devitalized limbs occurs in 
a subset of patients and is characterized by excessive 
licking or chewing of the toes or hock. Application 
of a loose fitting bandage barrier is usually effective. 
Conclusively, it is important to manually void the uri-
nary bladder if necessary, and maintain a clean and 
comfortable bedding. 
>48 hours post-ATE
The vast majority of the cats are more comfort-
able and happier at home after the initial 72 hours 
post-ATE. Oral analgetics, e.g. buprenorphine, should 
be continued at home if there would be still any dis-
comfort present at the time of discharge. The aspirin 
and clopidogrel can be continued for longer term 
prophylaxis (Hogan, 2017). Stool softeners, such as 
lactulose, can be administrated in case of hard stools 
or constipation. The owner should be informed thor-
oughly regarding the cat’s need for relatively inten-
sive daily home medical care, risk of ATE recurrence, 
prognosis of the underlying cardiomyopathy and ne-
cessity of monitoring the resting respiratory rate, as 
well as expected costs of treatment and follow-up. 
Detailed instructions should be given to the owner re-
garding the physiotherapy and early identification of 
possible chronic complications from aortic infarction, 
e.g. self-mutilation, limb necrosis requiring amputa-
tion and limb contracture (Fuentes, 2012) (Figures 5 
and 6).
Rehabilitation therapy may be instituted after the 
first two days of ATE and includes gentle passive 
range of motion, supporting the cat in a standing posi-
tion to retrain normal placement of the pelvic limbs 
and feet, and very gentle antegrade massage from the 
feet to the hip. Owners can be trained how to adminis- 
ter rehabilitation therapy, which can be performed 
every six hours for the first one to two weeks of reco-
very, then tapered depending on neuromotor status. In 
between session, cats are at risk of excoriation of the 
dorsal aspect of the limbs with affected pelvic limbs as 
these cats tend to move with the distal limbs extended 
behind them. The legs hence may require dressings 
to protect them. Limb edema may be observed days 
after the event as a consequence of severe muscle in-
jury (and predicts a poorer chance for full recovery) 
and should not be mistaken for an early sign of ATE 
(Bonagura, 2010). These complications are usually 
restricted to cats with very severe ischemic damage 
and it should be advised to recheck these patients 
every three to four days by the treating veterinarian to 
reassess limb function and the need for continued anal- 
gesia, presence of pulses, control of CHF signs and 
the absence of possible necrotic changes in the skin. 
Conclusively, cats with underlying cardiomyo-
pathy should be re-evaluated on a regular base via ap-
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propriated diagnostic modalities, e.g. thoracic radio- 
graphs and echocardiographic examination, and a 
therapy adjusted accordingly.
PREVENTION OF ATE
Given the dramatic presentation and guarded prog-
nosis, prevention of an ATE event is clearly prefer-
able. As already mentioned, cardiomyopathy is the 
most prevalent etiological cause, and ATE prevention 
is a standard part of cardiac patients with increased 
risk. However, cats with non-cardiac diseases pre-
disposing them to ATE, such as hyperthyroidism, 
protein-losing enteropathy or nephropathy (rare in 
cats) and pulmonary neoplasia, may also benefit from 
thromboprophylaxis in specific situations.  
Primary prevention
Primary prevention focuses on preventing an ini-
tial ATE event in cats that appear to be at risk; how-
ever, at this time, no studies on primary prevention of 
CATE in veterinary medicine are available. In some 
studies, it has been tried to define risk factors for the 
development of CATE. In a retrospective study on 
cats with HCM, it has been demonstrated that cats 
presenting with ATE have a significantly larger left 
atrial size, end-systolic left ventricular diameter and 
lower fractional shortening than asymptomatic cats 
or cats with CHF (Payne et al., 2010). Based on this 
report, some specialists recommend primary preven-
tion in cats with an end-systolic diameter greater than 
1.7 cm, a left atrium-to-aortic ratio greater than 2.0 
or auricular emptying velocities of <20cm/s. Primary 
prevention is also indicated in cats with spontaneous 
contrast or ‘smoke’ in the left atrium on echocardio-
graphy (Schober and Maerz, 2006). 
Secondary prevention
Secondary prevention focuses on preventing a sub-
sequent ATE event in cats that have a history of ATE. 
In several studies, a recurrence rate of cats receiving 
some antithrombotic therapy has been reported from 
17% to 75%, with a one-year recurrence rate of 25% 
to 50%. The FATCAT study has shown clopidogrel to 
be superior to aspirin with a ATE recurrence rate of 
49% (versus 75% for aspirin) and a one-year recur-
rence rate of 36% (versus 64% for aspirin). Clopido-
grel was also associated with longer median time to 
ATE event (443 days) than aspirin (192 days) (Ho-
gan et al., 2015). Cats that have already experienced 
an ATE event have an objectively demonstrated in-
creased risk, so prevention is recommended in all cats 
with an objective or suspected history of ATE. 
CONCLUSION
Feline arterial thromboembolism is thought to 
be an uncommon disease, with a prevalence ranging 
from 0.3-0.6% in practice (Smith et al., 2003; Borgeat 
et al., 2014). Despite the low prevalence, it is con-
sidered to be one of the most distressing conditions 
encountered in feline practice, because of the lack of 
preceding signs, the devastating clinical presentation 
and the generally poor prognosis. Given these condi-
tions, the majority of these affected cats are currently 
euthanized at the time of diagnosis. Although the clin-
ical signs of CATE are dramatic and acute survival 
is relatively low, the majority of these cats are fairly 
stable within 48-72 hours. Therefore, owners should 
consider therapy for at least the first 72 hours and not 
make a decision for immediate euthanasia (Hogan, 
2017). Despite the generally poor prognosis, with sur-
vival rates ranging from 33% to 39%, a subpopulation 
of these patients may have long-term survival. Some 
cats survive over a year with a satisfying quality of 
life, in case of adequate treatment and follow-up. Af-
fected cats may display positive prognostic factors 
indicative of higher survival rate and better mid- to 
long-term prognosis, namely the absence of CHF, 
rectal temperature at the moment of presentation 
>37.2°C, (partial) presence of motor function, and 
the site of thromboembolism and associated affected 
limbs or other organs (Schoeman, 1999; Borgeat et 
al., 2014). A correct identification of specific prog-
nostic factors obtained from results of physical ex-
amination and further testing, enables the veterinarian 
to give the owner the best possible advice regarding 
further treatment, management and prognosis. Cur-
rent treatment should always consist of initial clinical 
stabilization with adequate and adjusted analgetic and 
antithrombotic treatment. 
Furthermore, diuretic therapy should be adminis-
tered if concomitant CHF is diagnosed. At the mo-
ment, there is no fixed treatment protocol, several 
drug classes can be considered and treatment approach 
should always be evaluated individually. Prospec-
tive studies regarding the primary prevention of ATE 
events are currently lacking in feline medicine, but for 
secondary prevention, clopidogrel has been shown su-
perior to aspirin (Hogan et al., 2015). Conclusively, 
further studies are needed to investigate possible al-
ternative therapies and preventive measurements.
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